Explore

Trendline Trendline
UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with Novel T-cell Engagers
Trendline Trendline
UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies
Trendline Trendline
UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers
Trendline Trendline
UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal

UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal

UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal
Trendline Trendline
UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease
Trendline Trendline
Pharmaceutical Industry Utilizes Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Industry Utilizes Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Industry Utilizes Protein Biomarkers to Mitigate Drug Development Risks
Trendline Trendline
Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions
Rapid Read Rapid Read
NYU's Innovative Approach to Health Research Aims to Transform Medical Solutions

NYU's Innovative Approach to Health Research Aims to Transform Medical Solutions

New York University (NYU) is revolutionizing its approach to health research through the Institute for Engineering Health. This initiative focuses on disease states rather than traditional academic disciplines, fostering cross-disciplinary collaboration. The institute brings together experts from various fields, such as immunology, computational biology, and materials science, to tackle complex health issues like allergic asthma. Notable projects include a device for detecting airborne pathogens and navigation technology for visually impaired subway riders. The institute's leader, Jeffrey Hubbell, emphasizes a shift from inhibiting harmful biological processes to promoting beneficial ones, requiring a new toolkit and cross-disciplinary expertise.
Trendline Trendline
AGC Biologics Partners with Novelty Nobility to Advance Bispecific Drug Candidate for Retinal Diseases

AGC Biologics Partners with Novelty Nobility to Advance Bispecific Drug Candidate for Retinal Diseases

AGC Biologics Partners with Novelty Nobility to Advance Bispecific Drug Candidate for Retinal Diseases
Trendline Trendline
Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment

Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment

Amgen Launches Phase 3 Study for MariTide, Aiming to Revolutionize Obesity Treatment